FIELD: medicine; endocrinology.
SUBSTANCE: invention relates to medicine, namely to endocrinology, it can be used for body weight reduction, obesity treatment, appetite suppression or acceleration of a weight loss in a human subject. At least one osmotic delivery device containing exenatide is implanted in a human subject for providing continuous exenatide injection from at least one osmotic delivery device, wherein continuous injection includes the first period of continuous exenatide injection in the first doze with the following second period of continuous exenatide injection in the second doze, while the specified second doze is greater than the first doze. Stable exenatide delivery in therapeutic concentration is achieved during 5 days after each implantation of osmotic delivery device. Stable exenatide delivery is continuous during at least 3 months.
EFFECT: body weight reduction and tolerance of high doses of exenatide are achieved due to the increase in exenatide doze during extended phase of its injection.
28 cl, 21 dwg, 20 tbl, 4 ex
Title |
Year |
Author |
Number |
FAST ACHIEVEMENT AND/OR COMPLETION OF SUBSTANTIAL STABLE DRUG DELIVERY |
2010 |
- Alessi Tomas R.
- Laski Kennet L.
|
RU2547990C2 |
FAST ACHIEVEMENT AND/OR TERMINATION OF SIGNIFICANT STABLE DRUG DELIVERY |
2014 |
- Alessi Tomas R.
- Laski Kennet L.
|
RU2703471C2 |
METHOD OF TREATING INSULIN-INDEPENDENT DIABETES AND OBESITY, OSMOTIC DELIVERY SYSTEM AND METHOD FOR MAKING IT |
2008 |
- Alessi Tomas R.
- Merser Rajan D.
- Roloff Katrin M.
- Jan Bin
|
RU2440097C2 |
POLYMER STABILIZING AGENTS FOR IMPLANTABLE DRUG DELIVERY DEVICES |
2021 |
- Olf, Ryan
- Gordon, Lyle
- Roorda, Wouter
|
RU2836137C1 |
PREVENTING HYPOGLYCAEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS |
2012 |
- Sil'Vestr Luiz
- Boka Gabor
- Miossek Patrik
|
RU2572703C2 |
POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS |
2017 |
- Blekuell, Uilyam
- Srivastava, Ved P.
- Paulik, Mark A.
- Yang, Endryu
- Khanter, Iii, Robert Nil
- Dok, Stiven Tomas
|
RU2760007C2 |
LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT |
2012 |
- Rus Peter
- Silvestr Luiz
- Moissek Patrik
- Penke Zhan-Lui
- Enselen-Meri Anes
|
RU2623023C2 |
METHOD FOR PREVENTING GLP-1 SIDE EFFECTS |
2008 |
- Richardson Piter
- Boumen Robert A.
- Kostello Donal'D
|
RU2474415C2 |
METHOD OF PRODUCING PRODUCTS CONTAINING STABILIZED ACTIVE SUBSTANCES AND COMPOSITIONS CONTAINING THEREOF |
2015 |
|
RU2702690C2 |
OCTREOTIDE DELIVERY FROM DRY DOSAGE FORMS |
2009 |
|
RU2518745C2 |